CD274 and non-small cell lung carcinoma: In total, 129 patients with pre-treated (median of three prior lines of treatment) advanced cancers were enrolled to receive either 180, 360, 720, or 960 mg of sotorasib as part of dose escalation/expansion cohorts in phase I. Of the 59 patients included with NSCLC, the majority had previously received anti-programmed cell death ligand-1 (PDL-1) therapy (89.8%), and all had received prior platinum-based therapy.